DG remarks and links for COVID-19 press briefing, 12 March, 2021

WHO Media ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

No images? Click here Friday 12 March, 2021 Please find enclosed the link of the WHO Director-General's statement as well as other materials from the COVID-19 media briefing on 12 March: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-12-march-2021 WHO’s Global Advisory Committee on Vaccine Safety systematically reviews safety signals, and is carefully assessing the current reports on the AstraZeneca vaccine.  More than 335 million doses of COVID-19 vaccines have been administered globally so far, and no deaths have been found to have been caused by COVID-19 vaccines. But at least 2.6 million people have been killed by the virus.   Today, WHO gave emergency use listing to Johnson & Johnson’s COVID-19 vaccine, making it the fourth vaccine to receive WHO’s approval. Emergency use listing is the green light for a vaccine to be procured and rolled out by COVAX. The COVAX Facility has booked 500 million doses of the J&J vaccine, and we look forward to receiving them as soon as possible.   Media briefing audio link (Length 1hrs 03mins):  https://terrance.who.int/mediacentre/presser/WHO-AUDIO_Emergencies_Coronavirus_Press_Conference_12MAR2021.mp3 News edit link (TRT  4mins 51sec):  https://who.canto.global/b/G12BI Media assets and information on COVID-19 https://who.canto.global/v/coronavirus RELATED WHO adds Janssen vaccine to list of safe and effective emergency tools against COVID-19 The World Health Organization (WHO) today listed the COVID-19 vaccine Ad26.COV2.S, developed by Janssen (Johnson & Johnson), for emergency use in all countries and for COVAX roll-out.  ACT-A prioritized strategy and budget for 2021 The Access to COVID-19 Tools (ACT) Accelerator Strategy and Budget will be periodically updated to reflect the evolving epidemiological situation, knowledge of COVID-19, COVID-19 products and pipeline, and financing requirements.  Topics covered include: key achievements, priorities in 2021, maximizing impact, the funding gap, complementary activities and investments, and the economic case for investing in the ACT-Accelerator. More.  Media contacts: mediainquiries@who.int   You are receiving this NO-REPLY email because you are included on a WHO mail list. If you have been forwarded this update you can click here to subscribe. Do not reply to media@campaign.who.int as it is an unmonitored mailbox. Journalists may write to mediainquiries@who.int.   World Health Organization, Avenue Appia 20, 1202 Geneva 27, Switzerland    Share    Tweet    Share    Forward  Preferences  |  Unsubscribe